Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area

Authors: Ji-Jin Yao, Feng-Ting Zhu, Jun Dong, Zi-Bin Liang, Le-Wei Yang, Shao-Yi Chen, Wang-Jian Zhang, Wayne R. Lawrence, Fan Zhang, Si-Yang Wang, Ying Sun, Guan-Qun Zhou

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Findings remain unclear whether neutrophil-to-lymphocyte ratio (NLR) detrimentally affects advanced nasopharyngeal carcinoma (NPC) prognosis. We aim to evaluate the prognostic value of NLR in patients with NPC based on a large-scale cohort from an endemic area.

Methods

We selected patients retrospectively from a cohort examining long-term cancer outcomes following diagnosis. Neutrophil counts and lymphocyte counts were assessed prior to treatment. Kaplan–Meier method and log-rank test were used to calculate and compare survival outcomes. Additionally, Cox proportional hazards model was utilized to carry out univariate and multivariate analyses.

Results

Between October 2009 and August 2012, we enrolled 1550 consecutive NPC patients staged II-IVB. The median value of NLR was 2.27 (interquartile range [IQR], 1.71–3.12). Determined by operating characteristic curve using overall survival (OS) as an endpoint, the cutoff value for NLR was 2.50. At 5 years, NLR > 2.50 was associated with inferior OS (90.3% vs 82.5%; P < 0.001), distant metastasis-free survival (DMFS, 89.4% vs 85.0%; P = 0.014), and progression-free survival (PFS, 80.9% vs 76.5%; P = 0.031) than NLR ≤2.50. In multivariate analysis, NLR was found to be a significant prognostic factor for OS (HR, 1.72; 95% CI, 131–2.24; P < 0.001), DMFS (HR, 1.45; 95% CI, 1.10–1.92; P = 0.009), and PFS (HR, 1.29; 95% CI, 1.04–1.59; P = 0.021).

Conclusion

Pretreatment NLR independently affects survival. Our findings suggest that NLR measurements will be of great clinical significance in the management of NPC.
Literature
1.
go back to reference Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–9.CrossRef Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–9.CrossRef
2.
go back to reference Lee AW, Ng WT, Chan LK, et al. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol. 2012;48(10):1007–13.CrossRef Lee AW, Ng WT, Chan LK, et al. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol. 2012;48(10):1007–13.CrossRef
3.
go back to reference Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.CrossRef Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.CrossRef
4.
go back to reference Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119:963–70.CrossRef Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119:963–70.CrossRef
5.
go back to reference Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19:2208–15.CrossRef Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19:2208–15.CrossRef
6.
go back to reference Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRef Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRef
7.
go back to reference Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64.CrossRef Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64.CrossRef
8.
go back to reference Viers BR, Boorjian SA, Frank I, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014;66(6):1157–64. Viers BR, Boorjian SA, Frank I, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014;66(6):1157–64.
9.
go back to reference An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol. 2011;32(2):317–24.CrossRef An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol. 2011;32(2):317–24.CrossRef
10.
go back to reference Sun W, Zhang L, Luo M, Hu G, Mei Q, Liu D, Long G, Hu G. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2016;38(Suppl 1):E1332–40.CrossRef Sun W, Zhang L, Luo M, Hu G, Mei Q, Liu D, Long G, Hu G. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2016;38(Suppl 1):E1332–40.CrossRef
11.
go back to reference Chua ML, Tan SH, Kusumawidjaja G, Shwe MT, Cheah SL, Fong KW, Soong YL, Wee JT, Tan TW. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer. 2016;67:119–29.CrossRef Chua ML, Tan SH, Kusumawidjaja G, Shwe MT, Cheah SL, Fong KW, Soong YL, Wee JT, Tan TW. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer. 2016;67:119–29.CrossRef
12.
go back to reference Yin J, Qin Y, Luo YK, Feng M, Lang JY. Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore). 2017;96(29):e7577.CrossRef Yin J, Qin Y, Luo YK, Feng M, Lang JY. Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore). 2017;96(29):e7577.CrossRef
13.
go back to reference Takenaka Y, Kitamura T, Oya R, Ashida N, Shimizu K, Takemura K, Yamamoto Y, Uno A. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis. PLoS One. 2017;12(7):e0181478.CrossRef Takenaka Y, Kitamura T, Oya R, Ashida N, Shimizu K, Takemura K, Yamamoto Y, Uno A. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis. PLoS One. 2017;12(7):e0181478.CrossRef
14.
go back to reference Amin M. American joint committee on cancer. In: AJCC Cancer staging manual. New York: Springer; 2016. Amin M. American joint committee on cancer. In: AJCC Cancer staging manual. New York: Springer; 2016.
15.
go back to reference Yao JJ, Yu XL, Zhang F, et al. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chin J Cancer. 2017;36(1):26.CrossRef Yao JJ, Yu XL, Zhang F, et al. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chin J Cancer. 2017;36(1):26.CrossRef
16.
go back to reference ICRU. Report. Vol. 62: prescribing, recording, and reporting photon beam therapy. International Commission on Radiation Units and Measurements: Maryland; 1999. ICRU. Report. Vol. 62: prescribing, recording, and reporting photon beam therapy. International Commission on Radiation Units and Measurements: Maryland; 1999.
17.
go back to reference Report ICRU. Vol. 83: prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). International Commission on Radiation Units and Measurements: Maryland; 2010. Report ICRU. Vol. 83: prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). International Commission on Radiation Units and Measurements: Maryland; 2010.
18.
go back to reference Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Medicine. 2017;6(1):310–9.CrossRef Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Medicine. 2017;6(1):310–9.CrossRef
19.
go back to reference Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and metaanalysis. J Natl Cancer Inst. 2014;106:dju124. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and metaanalysis. J Natl Cancer Inst. 2014;106:dju124.
20.
go back to reference Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.PubMed Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.PubMed
21.
go back to reference Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRef Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRef
22.
go back to reference Kim HS, Ku JH. Systemic inflammatory response based on neutrophil-tolymphocyte ratio as a prognostic marker in bladder cancer. Dis Markers. 2016;2016:8345286.PubMedPubMedCentral Kim HS, Ku JH. Systemic inflammatory response based on neutrophil-tolymphocyte ratio as a prognostic marker in bladder cancer. Dis Markers. 2016;2016:8345286.PubMedPubMedCentral
24.
go back to reference Hegmans JP, Aerts JG. Immunomodulation in cancer. Curr Opin Pharmacol. 2014;17:17–21.CrossRef Hegmans JP, Aerts JG. Immunomodulation in cancer. Curr Opin Pharmacol. 2014;17:17–21.CrossRef
25.
go back to reference Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.CrossRef Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.CrossRef
26.
go back to reference Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int J Cancer. 2014;134:2755–63.CrossRef Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int J Cancer. 2014;134:2755–63.CrossRef
27.
go back to reference J S, Gerger A, Liegl–Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135:362–70.CrossRef J S, Gerger A, Liegl–Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135:362–70.CrossRef
28.
go back to reference Thurner EM, Krenn–Pilko S, Langsenlehner U, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer. 2015;51:610–9.CrossRef Thurner EM, Krenn–Pilko S, Langsenlehner U, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer. 2015;51:610–9.CrossRef
29.
go back to reference Chang H, Gao J, Xu BQ, et al. Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution. Clin Oncol. 2013;25(11):639–46.CrossRef Chang H, Gao J, Xu BQ, et al. Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution. Clin Oncol. 2013;25(11):639–46.CrossRef
Metadata
Title
Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area
Authors
Ji-Jin Yao
Feng-Ting Zhu
Jun Dong
Zi-Bin Liang
Le-Wei Yang
Shao-Yi Chen
Wang-Jian Zhang
Wayne R. Lawrence
Fan Zhang
Si-Yang Wang
Ying Sun
Guan-Qun Zhou
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5236-2

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine